Latest news

Crofelemer

A proprietary gastro-intestinal compound in clinical development for four distinct product indications

Join Our Mailing List
Email:  

publications

Crofelemer, a novel agent for treatment of secretory diarrhea

A Double Blind, Randomized, Placebo-Controlled Phase II Study to Assess the Safety and Efficacy of Orally Administered SP-303 for the Symptomatic Treatment of Diarrhea in Patients With AIDS

Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels

Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients

Safety and efficacy of a novel anti-secretory anti-diarrheal agent Crofelemer (NP-303), in the treatment of adult acute infectious diarrhea and cholera, with or without the use of antibiotics

A possible new drug to treat acute diarrhea from cholera and other conditions

Crofelemer in the treatment of secretory diarrhea

Crofelemer improves acute infectious diarrhea symptoms

Evaluation of safety and efficacy of a novel anti-secretory anti-diarrheal agent Crofelemer (NP-303), in combination with a single oral dose of azithromycin for the treatment of acute dehydrating diarrhea caused by Vibrio cholera

A novel extract SB-300 from the stem bark latex of Croton lechleri inhibits CFTR-mediated chloride secretion in human colonic epithelial cell

A novel plant-derived inhibitor of cAMP-mediated fluid and chloride secretion

A new therapy for HIV-Associated diarrhea improves quality of life

SP-303, an antiviral oligomeric proanthocyanidin from the latex of Croton lechleri

A Double Blind, Randomized, Placebo-Controlled Study of SP-303 (Provir) in the Symptomatic Treatment of Acute Diarrhea Among Travelers to Jamaica and Mexico

Lisa A. Conte, (2009). Enteric Disease impact on Global Health, Human Rights, and Environmental Degradation, www.huffingtonpost.com